Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
Noosa News16 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
General17 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle
-
Business22 hours agoDown 20% this year, here are 3 reasons why I’m still loading up on Amazon stock
-
General22 hours agoStocks, dollar sink as trade war roils markets